Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome
Phase 4
Completed
- Conditions
- Dyslipidemia
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 75
- Registration Number
- NCT00385658
- Locations
- 🇨🇭
Novartis Pharma AG, Basel, Switzerland
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 21
- Registration Number
- NCT00380445
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇩🇪Novartis Investigative Site, Investigative Centers, Germany
A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00380380
- Locations
- 🇩🇪
Munich, 81377, Germany, Munich, Germany
Topical Diclofenac Gel in Patients With Superficial Inflammation of the Veins
Phase 4
Completed
- Conditions
- Superficial Thrombophlebitis of the Upper Limb
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00377806
- Locations
- 🇩🇪
Novartis, Nürnberg, Germany
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 43
- Registration Number
- NCT00376259
- Locations
- 🇺🇸
Novartis, San Diego, California, United States
🇨🇳Novarits, Kaohsuing, Taiwan
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions
Phase 3
Terminated
- Conditions
- Breast Cancer With Bone Metastasis
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00372710
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
Phase 4
Completed
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 228
- Registration Number
- NCT00369161
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00367939
Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 275
- Registration Number
- NCT00367978
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2007-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 370
- Registration Number
- NCT00368134
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath